NEW YORK (GenomeWeb) – Foundation Medicine said last week that it is advancing a blood-based version of its tumor mutational burden test as a companion diagnostic to Roche/Genentech’s immunotherapy drug Tecentriq (atezolizumab) in first-line treatment of non-small cell lung cancer patients.
The assay is moving forward in two clinical trials. In a single-arm trial called B-F1RST, investigators are retrospectively analyzing blood-based TMB status in NSCLC patients treated with first-line Tecentriq regardless of their biomarker status.